{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:33:20Z","timestamp":1757612000646,"version":"3.44.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Visceral leishmaniasis (VL) is a fatal disease if left untreated. Globally, at least 50% of VL cases are reported to be children younger than 15 years, with a higher incidence among males. VL is intrinsically associated with poverty and poor social determinants of health. Malnutrition and immune suppression are risk factors for severe VL, making children particularly vulnerable to this disease. Available treatment options vary depending on the eco-epidemiological context, but are in general suboptimal, especially for children. In 2023, the World Health Organization convened a paediatric drug optimization exercise (PADO) for VL, bringing together more than 60 experts globally in the field of VL to identify formulations of VL medicines to prioritize for development to address the specific needs of children. The group prioritized a 20\u2005mg scored, dispersible tablet formulation of miltefosine and an oral solid dosage form of amphotericin B, acknowledging recent developments in allometric dosing for miltefosine and ongoing research for the development of oral amphotericin B. For miltefosine, this prompted an ongoing update of the WHO Prequalification Expression of interest to promote generic manufacturing. A compound with a new mechanism of action, LXE408, which is currently being investigated in Phase II, was included in the PADO watch list, signalling that paediatric investigations should start as soon as enough data are available from adult studies, not to delay access to latest available innovations for children with VL.<\/jats:p>","DOI":"10.3389\/fped.2025.1635252","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:34:38Z","timestamp":1756964078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization and prioritization of paediatric drugs for visceral leishmaniasis"],"prefix":"10.3389","volume":"13","author":[{"given":"Tiziana","family":"Masini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Nilce Silveira","family":"Maia-Elkhoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khechar N.","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Penazzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha Yuri Oshiro","family":"Branco Valadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abate","family":"Beshah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Warusavithana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"year":"","key":"B1","article-title":"Control of the leishmaniases: WHO TRS N\u00b0949. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22\u201326 March 2010"},{"year":"2024","key":"B2","article-title":"Leishmaniasis fact sheet. Geneva: World Health Organization"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1098\/rspb.1993.0123","article-title":"Malnutrition, age and the risk of parasitic disease: visceral leishmaniasis revisited","volume":"254","author":"Dye","year":"1993","journal-title":"Proc Biol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/infdis\/156.6.1030","article-title":"Malnutrition as a risk factor for severe visceral leishmaniasis","volume":"156","author":"Cerf","year":"1987","journal-title":"J Infect Dis"},{"key":"B5","first-page":"653","volume-title":"Global Leishmaniasis Surveillance Updates 2023: 3 Years of the NTD Road Map","author":"Jain","year":"2024"},{"year":"2021","key":"B6","article-title":"Paediatric drug optimization standard procedure. Geneva: World Health Organization"},{"year":"2023","key":"B7","article-title":"Paediatric drug optimization for neglected tropical diseases: meeting report, September 2023. Geneva: World Health Organization"},{"volume-title":"WHO guidelines for the Treatment of Visceral Leishmaniasis in HIV co-infected patients in East Africa and South-East Asia","year":"2022","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India","volume":"38","author":"Bhattacharya","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/BF02763048","article-title":"Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study","volume":"73","author":"Singh","year":"2006","journal-title":"Indian J Pediatr"},{"article-title":"Weight-band based simplification of oral allometric miltefosine dosing in pediatric patients with visceral leishmaniasis in Eastern Africa","year":"2025","author":"Mazariegos Herrera","key":"B12"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1177","DOI":"10.1093\/cid\/ciac643","article-title":"Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: a randomized, controlled, multicountry trial","volume":"76","author":"Musa","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0011780","DOI":"10.1371\/journal.pntd.0011780","article-title":"Safety and efficacy of paromomycin\/miltefosine\/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: a phase II, open label, randomized, parallel arm study","volume":"17","author":"Younis","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0012242","DOI":"10.1371\/journal.pntd.0012242","article-title":"A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh","volume":"18","author":"Sundar","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/pharmaceutics11100518","article-title":"Innovations in pediatric drug formulations and administration technologies for low resource settings","volume":"11","author":"Gerrard","year":"2019","journal-title":"Pharmaceutics"},{"volume-title":"Guideline for the Treatment of Leishmaniasis in the Americas","year":"2022","key":"B17"},{"key":"B18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.4269\/ajtmh.18-0949","article-title":"Natural resistance of leishmania infantum to miltefosine contributes to the low efficacy in the treatment of visceral leishmaniasis in Brazil","volume":"101","author":"Carnielli","year":"2019","journal-title":"Am J Trop Med Hyg"},{"article-title":"Amphotericin B, an oral lipid nanocrystal for cryptococcal meningitis, Phase 2 results: David Boulware, ECCMID 2023 [video]","year":"2023","author":"Boulware","key":"B19"},{"volume-title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 (EnACT3)","year":"2023","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/pharmaceutics14112316","article-title":"Review of novel oral amphotericin B formulations for the treatment of parasitic infections","volume":"14","author":"Wasan","year":"2022","journal-title":"Pharmaceutics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.1371\/journal.pntd.0000913","article-title":"A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine model","volume":"4","author":"Wasan","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/600105","article-title":"Highly effective oral amphotericin B formulation against murine visceral leishmaniasis","volume":"200","author":"Wasan","year":"2009","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.apar.2018.09.002","article-title":"Challenges and lessons from conducting a paediatric clinical trial in sub-saharan Africa: the case of the praziquantel oral dispersible tablets phase II study in c\u00f4te d\u2019Ivoire","volume":"103","author":"N'Goran","year":"2019","journal-title":"Adv Parasitol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s13071-022-05546-7","article-title":"Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children","volume":"15","author":"Al-Obaidi","year":"2022","journal-title":"Parasit Vectors"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1635252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:34:40Z","timestamp":1756964080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1635252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":25,"alternative-id":["10.3389\/fped.2025.1635252"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1635252","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1635252"}}